COLL News and Press, Collegium Pharmaceutical Inc. From 02/10/20

STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625% convertible senior notes due 2026 (the “notes”) in a public offering registered un...

Shares of Collegium Pharmaceutical   (NASDAQ: COLL) were sinking 13.6% as of 3:24 p.m. EST on Monday. The decline came after the drugmaker announced a $125 million proposed offering of senior convertible notes. The bad news with Collegium's proposed offering is that it means that dilutio...

Collegium Pharmaceutical ( COLL ) is a name that I covered with great interest in the past, as I generally liked the positioning of the firm. It has been nearly a year since I last updated the thesis as I saw some comforting developments at the time. The company has seen a few breakthrough...

Gainers: vTv Therapeutics (NASDAQ: VTVT )  +57% . More news on: vTv Therapeutics Inc., Taubman Centers, Inc., NanoViricides, Inc., Stocks on the move, , Read more ...

Collegium Pharmaceutical ( COLL -10.4% ) is down in early trade in response to its $125M public offering of convertible senior notes due 2026. More news on: Collegium Pharmaceutical, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Myomo (NYSEMKT: MYO ) -19% . More news on: Myomo, Inc., Arbutus Biopharma Corporation, Biohaven Pharmaceutical Holding Company Ltd., Stocks on the move, , Read more ...

Shares of Collegium Pharmaceutical (NASDAQ: COLL) jumped more than 20% today after the company announced an agreement to purchase the U.S. rights to the Nucynta franchise from Assertio Therapeutics for $375 million. The opioid franchise includes Nucynta extended-release and immediate-release...

Gainers: Benitec Biopharma (NASDAQ: BNTC )  +51% . More news on: Benitec Biopharma Limited, Assertio Therapeutics, Inc., Ocwen Financial Corporation, Stocks on the move, , Read more ...

Assertio Therapeutics (NASDAQ: ASRT ) +63%  on buying Nucynta U.S. rights from Assertio in $375M deal. More news on: Assertio Therapeutics, Inc., Yield10 Bioscience, Inc., Telenav, Inc., Stocks on the move, Read more ...

Collegium Pharmaceutical (NASDAQ: COLL ) +8.3% after-hours on news it agrees to acquire the U.S. rights to the Nucynta franchise from Assertio Therapeutics (NASDAQ: ASRT ) for $375M; ASRT +56.7% . More news on: Collegium Pharmaceutical, Inc., Assertio Therapeutics, Inc., Healthcare st...